Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BTAI BioXcel Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: BTAI
Price (delayed)
$1.53
Market cap
$9.27M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$12.85
Enterprise value
$83.78M
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically
Highlights
BTAI's EPS has surged by 84% year-on-year and by 45% since the previous quarter
BioXcel Therapeutics's net income has surged by 74% YoY and by 33% QoQ
The equity has declined by 25% year-on-year but it is up by 3.1% since the previous quarter
BTAI's revenue is down by 18% since the previous quarter but it is up by 5% year-on-year
The gross profit has plunged by 153% YoY
BTAI's gross margin has dropped by 151% year-on-year
Key stats
What are the main financial stats of BTAI
Market
Valuations
Earnings
Shares outstanding
6.06M
Market cap
$9.27M
Enterprise value
$83.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
45.24
Revenue
$1.85M
Gross profit
-$226,000
Operating income
-$53.18M
Net income
-$40.06M
EBIT
-$24.55M
EBITDA
-$24.24M
Free cash flow
-$66.36M
Per share
Balance sheet
Liquidity
EPS
-$12.85
EPS diluted
-$12.85
Free cash flow per share
-$13.73
Book value per share
-$16.44
Revenue per share
$0.38
TBVPS
$7.98
Total assets
$38.57M
Total liabilities
$128.74M
Debt
$105.53M
Equity
-$90.17M
Working capital
$12.23M
Debt to equity
-1.17
Current ratio
1.48
Quick ratio
1.21
Net debt/EBITDA
-3.07
Margins
Efficiency
Dividend
EBITDA margin
-1,308.9%
Gross margin
-12.2%
Net margin
-2,163.2%
Operating margin
-2,871.5%
Return on assets
-83.8%
Return on equity
N/A
Return on invested capital
-28.1%
Return on capital employed
-188.5%
Return on sales
-1,325.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BTAI stock price
How has the BioXcel Therapeutics stock price performed over time
Intraday
11.68%
1 week
21.43%
1 month
-14.04%
1 year
-94.13%
YTD
-74.41%
QTD
-24.63%
Financial performance
How have BioXcel Therapeutics's revenue and profit performed over time
Revenue
$1.85M
Gross profit
-$226,000
Operating income
-$53.18M
Net income
-$40.06M
Gross margin
-12.2%
Net margin
-2,163.2%
The gross profit has plunged by 153% YoY
BTAI's gross margin has dropped by 151% year-on-year
BTAI's net margin has surged by 75% year-on-year and by 18% since the previous quarter
BioXcel Therapeutics's net income has surged by 74% YoY and by 33% QoQ
Price vs fundamentals
How does BTAI's price correlate with its fundamentals
Growth
What is BioXcel Therapeutics's growth rate over time
Valuation
What is BioXcel Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
3.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
45.24
BTAI's EPS has surged by 84% year-on-year and by 45% since the previous quarter
The equity has declined by 25% year-on-year but it is up by 3.1% since the previous quarter
The price to sales (P/S) is 64% lower than the last 4 quarters average of 11.2
BTAI's revenue is down by 18% since the previous quarter but it is up by 5% year-on-year
Efficiency
How efficient is BioXcel Therapeutics business performance
BioXcel Therapeutics's ROIC has soared by 85% YoY and by 46% from the previous quarter
BTAI's return on sales has surged by 83% year-on-year and by 32% since the previous quarter
BioXcel Therapeutics's return on assets has increased by 46% YoY and by 17% QoQ
Dividends
What is BTAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BTAI.
Financial health
How did BioXcel Therapeutics financials performed over time
The total assets is 70% less than the total liabilities
The total assets has plunged by 53% YoY
BTAI's quick ratio is down by 49% year-on-year and by 10% since the previous quarter
The equity has declined by 25% year-on-year but it is up by 3.1% since the previous quarter
BioXcel Therapeutics's debt to equity has increased by 17% YoY but it has decreased by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.